A federal judge has ruled that two genes, which are linked to breast and ovarian cancer, cannot be patented and has struck down the previously awarded patents. While some applaud the decision, critics say the ruling could cripple future life-saving research. Elizabeth Brackett and her panel look at the impact of the divisive decision.

• Read the court ruling (nytimes.com)